Philips behaalt in het vierde kwartaal een vergelijkbare omzetgroei van 2% naar EUR 7,1 miljard en een verbetering van de gecorrigeerde EBITA van 13% naar EUR 842 miljoen

januari 26, 2016

Hoogtepunten vierde kwartaal 
  • De vergelijkbare omzet steeg met 2%, met name dankzij een groei van 4% van het HealthTech-portfolio
  • Gecorrigeerd voor valuta-effecten nam de orderontvangst toe met 15%, voornamelijk dankzij Noord-Amerika, China en West-Europa
  • De gecorrigeerde EBITA1) steeg met 50 basispunten naar 11,9% van de omzet en bedroeg EUR 842 miljoen
  • De EBITA bedroeg EUR 263 miljoen, ofwel 3,7% van de omzet
  • Een nettoverlies van EUR 39 miljoen onder invloed van eenmalige lasten, waaronder de eerder aangekondigde afbouw van pensioengerelateerde risico's, tegenover een nettowinst van EUR 134 miljoen in het vierde kwartaal van 2014
  • Een vrije kasstroom van EUR 740 miljoen, vergeleken met EUR 559 miljoen in het vierde kwartaal van 2014
  • Afsplitsingsproces van Philips Lighting verloopt volgens schema

Hoogtepunten hele jaar
  • De vergelijkbare omzet steeg met 2% naar EUR 24,2 miljard, met name door een groei van ruim 4% van het HealthTech-portfolio
  • Gecorrigeerd voor valuta-effecten nam de orderontvangst toe met 5%, voornamelijk dankzij Noord-Amerika en West-Europa
  • De gecorrigeerde EBITA steeg met 20 basispunten naar 9,2% van de omzet en bedroeg EUR 2,2 miljard
  • De EBITA bedroeg EUR 1,4 miljard, ofwel 5,7% van de omzet, tegenover EUR 821 miljoen, ofwel 3,8% van de omzet, in 2014
  • Het nettoresultaat bedroeg EUR 659 miljoen, vergeleken met EUR 411 miljoen in 2014
  • Een vrije kasstroom van EUR 325 miljoen, tegenover EUR 497 miljoen in 2014
  • Rendement op geïnvesteerd vermogen steeg naar 7,0%, tegenover 4,5% in 2014
  • Voorstel om het dividend te handhaven op EUR 0,80 per aandeel

Frans van Houten, CEO:
“Ook in het vierde kwartaal van 2015 verbeterde Philips de operationele resultaten ten opzichte van de overeenkomstige periode van 2014. We behaalden een stijging van de gecorrigeerde EBITA in alle drie de sectoren en genereerden een kasstroom uit operationele activiteiten van bijna EUR 1 miljard.

In het vierde kwartaal zagen we de omzet van Healthcare opnieuw groeien. Gecorrigeerd voor valuta-effecten nam de orderontvangst sterk toe met 15%, en ook de marges verbeterden ten opzichte van de overeenkomstige periode van 2014. Bij Consumer Lifestyle zagen we opnieuw een robuuste groei van alle onderdelen, met name bij Health & Wellness, terwijl verbeteringen van de productiviteit en de productmix resulteerden in aanzienlijk hogere marges. Lighting heeft haar resultaten weer verbeterd ten opzichte van de overeenkomstige periode van het voorgaande jaar. Dit is met name het gevolg van de aanhoudende groei van de vergelijkbare omzet en margeverbetering van de LED-activiteiten en van onze effectieve maatregelen om de neerwaartse markt voor conventionele verlichtingsproducten te compenseren.

Over het geheel genomen was 2015 een solide jaar voor Philips. Dit zien we terug in consistente resultaatverbeteringen, hoewel de macro-economische omstandigheden uitdagend blijven. Lighting heeft haar operationele resultaten weer verbeterd. Ons HealthTech-portfolio – bestaande uit de onderdelen Healthcare en Consumer Lifestyle – realiseerde een veelbelovende groei van de vergelijkbare omzet van ruim 4% over het jaar als geheel. Hieruit blijkt dat we beter in staat zijn om te profiteren van de mogelijkheden in deze grote en groeiende markt. De groei van 5% van het ordervolume van Healthcare is bemoedigend.

Voor 2016 verwachten we een bescheiden groei van de vergelijkbare omzet en zullen we voortbouwen op de verbetering van onze operationele resultaten over 2015. In het licht van de aanhoudende macro-economische tegenwind en de verdeling van kosten en omzet over het jaar verwachten we dat verbeteringen zichtbaar worden in de tweede helft van 2016."

1) De gecorrigeerde EBITA is het bedrijfsresultaat (EBIT) exclusief afschrijvingen op verworven immateriële activa, bijzondere waardeveranderingen van goodwill en overige immateriële activa, herstructureringslasten, overnamegerelateerde kosten en overige aanmerkelijke posten.

Quarterly Report
Fourth quarter and Annual Results 2015 - Quarterly Report

Quarterly Report
Fourth quarter and Annual Results 2015 - Quarterly Report Presentation

Conference call and audio webcast
A conference call with Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, to discuss the results, will start at 10:00AM CET. A live audio webcast of the conference call will be available through the link below.

Q4 2015 conference call audio webcast


More information about Frans van Houten and Abhijit Bhattacharya
Click here for Mr. van Houten's CV and images
Click here for Mr. Bhattacharya's CV and images

Philips launched the new range of Efficia patient monitors in Tanzania

Philips launched the new range of Efficia patient monitors in Tanzania

Expanding its portfolio of healthcare solutions for low-resource countries, Philips launched the new range of Efficia patient monitors in Tanzania for the delivery of high-quality care at affordable cost, even in remote areas. Moreover, Philips developed a new diagnostic device to help improve the diagnosis and treatment of pneumonia in countries such as Tanzania.

UCHealth deploys Philips IntelliSpace PACS to optimize its image sharing workflow, driving cost savings and enhancing patient care

UCHealth deploys Philips IntelliSpace PACS to optimize its image sharing workflow, driving cost savings and enhancing patient care

Philips and UCHealth, an integrated delivery network (IDN) in Colorado, USA, signed a multi-year agreement for the implementation of Philips’ IntelliSpace Picture Archiving and Communications Systems across the IDN to optimize its image sharing workflow, thereby enhancing patient care and driving projected USD 11 million cost savings over five years.

Philips was leading brand on ‘double 11’

Philips was leading brand on ‘double 11’

On China’s biggest day for online shopping, ‘double 11’, Philips was a leading brand in categories like Male Grooming, Beauty, Garment Care, Kitchen Appliances and Oral Healthcare, with some product ranges selling out within minutes. Male shaving products were particularly popular, with over half a million Philips shavers sold in 24 hours.

Oral Healthcare experienced double-digit growth

Oral Healthcare experienced double-digit growth

Oral Healthcare experienced double-digit growth, with very strong performance in North America, China and Germany, Austria & Switzerland. The Philips Sonicare 2 electric toothbrush range was cited by US retailer Target as one of the most popular items in their Black Friday pre-sale.

Philips and City of San Jose partner to deploy Philips SmartPoles pilot project

Philips and City of San Jose partner to deploy Philips SmartPoles pilot project

Building on the company’s leadership in connected lighting, Philips entered into a global strategic alliance with Cisco to address the growing worldwide office market. Integrating Philips’ connected LED lighting system with Cisco’s IT network will save energy, improve building efficiency, and enhance employee well-being and productivity.

Philips and City of San Jose partner to deploy Philips SmartPoles pilot project combining energy efficient LED street lighting with wireless broadband technology from Ericsson

Philips and City of San Jose partner to deploy Philips SmartPoles pilot project combining energy efficient LED street lighting with wireless broadband technology from Ericsson

Expanding on Philips’ smart street lighting offering, Los Angeles and San Jose are the first cities to benefit from Philips LED street lighting combined with wireless broadband technology from Ericsson. Philips SmartPoles will expand wireless broadband coverage, reduce energy usage by more than 50%, and provide brighter, safer streets at night.

Philips and Banyan Biomarkers partner to develop and commercialize new handheld blood test to detect and evaluate concussions

Philips and Banyan Biomarkers partner to develop and commercialize new handheld blood test to detect and evaluate concussions

Philips and Banyan Biomarkers entered into a joint development agreement to develop and commercialize a new handheld blood test to detect concussion. The partnership will broaden the application of Philips’ handheld diagnostics system and will strengthen its competitive position in pointof-care diagnostics for acute care settings, a new growth market for Philips.

Philips adds Ledra Brands as its 600th member to its industry leading EnabLED Licensing Program for LED Luminaires and Retrofit Bulbs

Philips adds Ledra Brands as its 600th member to its industry leading EnabLED Licensing Program for LED Luminaires and Retrofit Bulbs

Philips welcomed the 600th member to its LED Luminaires and Retrofit Bulbs Licensing Program, which gives licensees access to its wide portfolio of patented LED system technologies and solutions. Philips has fostered the adoption of LED technology and LED industry growth through the licensing program since its inception in 2008.

Voor nadere informatie kunt u contact opnemen met:

Steve Klink
Philips Group Communications
Tel: +31 6 10888824
E-mail: steve.klink@philips.com 

Joost Akkermans
Philips Group Communications
Tel.: +31 6 3175 8996
E-mail: joost.akkermans@philips.com .

Over Koninklijke Philips N.V.:

Koninklijke Philips N.V. (NYSE: PHG; AEX: PHI) is een veelzijdige onderneming die actief is op het gebied van gezondheidszorg en welzijn. De onderneming is gericht op verbetering van de kwaliteit van leven van mensen door middel van zinvolle innovaties op het terrein van gezondheidszorg, lifestyle en verlichting. Het hoofdkantoor van Philips is gevestigd in Nederland. De onderneming boekte in 2014 een omzet van 21,4 miljard euro, heeft wereldwijd circa 106.000 medewerkers in dienst, en beschikt over verkoop- en servicepunten verspreid over meer dan 100 landen. De onderneming heeft een leidende positie op het gebied van cardiologie, spoedeisende zorg en zorg op afstand, energiezuinige verlichting en nieuwe verlichtingstoepassingen, en op het gebied van scheerapparaten en mondverzorgingsproducten. Meer nieuws over Philips vindt u op www.philips.nl/nieuwscentrum.  .

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
 
These factors include but are not limited to domestic and global economic and business conditions, developments within the euro zone, the successful implementation of Philips’ strategy and the ability to realize the benefits of this strategy, the ability to develop and market new products, changes in legislation, legal claims, changes in exchange and interest rates, changes in tax rates, pension costs and actuarial assumptions, raw materials and employee costs, the ability to identify and complete successful acquisitions, including Volcano, and to integrate those acquisitions into the business, the ability to successfully exit certain businesses or restructure the operations, the rate of technological changes, political, economic and other developments in countries where Philips operates, industry consolidation and competition. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see the Risk management chapter included in the Annual Report 2014 and the “Risk and uncertainties” section in the semi-annual financial report for the six months ended June 30, 2015.
 
Third-party market share data 
Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.
 
Use of non-GAAP information 
In presenting and discussing the Philips Group financial position, operating results and cash flows, management uses certain non-GAAP financial measures. These non-GAAP financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used in conjunction with the most directly comparable IFRS measures. Non-GAAP financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-GAAP measures to the most directly comparable IFRS measures is contained in this document. Further information on non-GAAP measures can be found in the Annual Report 2014.
 
Use of fair-value measurements 
In presenting the Philips Group financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2014. Independent valuations may have been obtained to support management’s determination of fair values.
 
Presentation 
All amounts are in millions of euros unless otherwise stated. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2014, unless otherwise stated. The presentation of certain prior-year information has been reclassified to conform to the current-year presentation.
 
In 2014, we announced plans to establish two standalone companies focused on the HealthTech and Lighting opportunities. The proposed separation of the Lighting business impacts all businesses and markets as well as all supporting functions and all assets and liabilities of the Group. Philips expects to complete the separation of the Lighting business in the first half of 2016. We expect to continue reporting in the existing structure until the changes in the way we allocate resources and analyze performance in the new structure have been completed..